Alzheimer's Treatment Enters a New Era: What the Latest Drug Approvals Mean
By Sanna the Weaver • Wed Feb 11 2026 • Health
For most of its history as a defined disease, Alzheimer's has been treated with drugs that manage symptoms without affecting the underlying biology. Cholinesterase inhibitors and memantine can modestly improve cognitive function in some patients, but they do not slow the accumulation of amyloid plaques and tau tangles in the brain that drive neurodegeneration. In 2023 and 2024, that changed. Lecanemab (Leqembi), developed by Eisai and Biogen, became the first anti-amyloid antibody to receive full FDA approval after demonstrating a 27% slowing of cognitive decline in early-stage Alzheimer's. Donanemab, developed by Eli Lilly, followed. In 2026, both drugs are in broad clinical use — and the gap between what these drugs can do and what patients and families hope they can do is becoming clearer. What the Drugs Do — and Don't Do Anti-amyloid antibodies like lecanemab work by clearing amyloid plaques from the brain. This mechanism is biologically significant — amyloid accumulation is a central feature of Alzheimer's pathology — but clearing the plaques does not restore function already lost. The 27% slowing of decline measured in clinical trials means that patients treated with lecanemab deteriorate more slowly than untreated patients — not that they get better, or that the disease stops. For patients and families, this distinction matters enormously. The expectation of a cure or a halt is often met with the reality of a slower slide. Who Benefits The drugs are approved for early Alzheimer's disease — patients with mild cognitive impairment or mild dementia who have confirmed amyloid accumulation, typically identified by PET scan or cerebrospinal fluid analysis. This is a specific and relatively small subset of the overall Alzheimer's population. Patients with moderate or advanced disease do not qualify, and the drugs have not shown benefit in those stages. The identification and screening requirements — amyloid PET scans cost $4,000 to $8,000 and are not covered by most insurance — are a major access barrier. "This is a foothold. Not a summit. The disease is slower. It is not stopped." — Alzheimer's Association Chief Science Officer, January 2026 What Is Coming The next generation of Alzheimer's research in 2026 is targeting tau — the other pathological protein in Alzheimer's disease — as well as neuroinflammation pathways implicated in driving neurodegeneration. Anti-tau antibodies are in Phase 2 and 3 trials. Notably, GLP-1 drugs (semaglutide) are being investigated for neuroinflammatory effects that may slow Alzheimer's progression through a completely different mechanism. And blood-based biomarker tests that can detect Alzheimer's pathology years before symptoms appear — enabling truly early intervention — are entering clinical practice, transforming the possibility of prevention rather than just treatment.